

PRESSRELEASE Stockholm 25 January 2021

The subscription period for warrants of series 2019/2021 begins today - Regulatory information

Today, on 25 January 2021, the subscription period begins for the warrants of series 2019/2021 that were issued in connection with ADDvise Group AB (publ)'s ("ADDvise" or the "Company") issue of units in 2019. The subscription period is between January 25 and February 8, 2021. Each warrant of series 2019/2021 entitles to subscribe for one (1) new share of series B in ADDvise at a price of SEK 0.65 per share of series B. If all warrants of series 2019/2021 are exercised, the Company will receive approximately SEK 28 million before issue costs. In order for the warrants not to expire without value, it is required that the holder subscribes for shares no later than February 8, 2021, or alternatively sells the warrants no later than February 4, 2021.

Summarized terms for the warrants of series 2019/2021

Subscription period: January 25, 2021 – February 8, 2021

Size of issue: 43,042,288 warrants of series 2019/2021. Upon full exercise, 43,042,288 shares will be issued and ADDvise receives approximately SEK 28 million before issue costs

Subscription price: SEK 0.65 per series B share

Last day of trading in warrants of series 2019/2021: February 4, 2021

Note that warrants that are not sold no later than February 4, 2021, or alternatively exercised by February 8, 2021, expire worthless. In order for your warrants of series 2019/2021 not to expire, you must subscribe for shares or sell your warrants.

Letter to warrant holders of series 2019/2021 is available at the Company's website, www.addvisegroup.se, and Mangold's website, www.mangold.se. Full terms for the warrants were included as part of the investment memorandum that was published on January 16, 2019. The investment memorandum and full terms and conditions for the warrants are also available at the above websites.

How to exercise the warrants

Nominee-registered warrants (custody)

Subscription and payment through the exercise of the warrant shall take place in accordance with instructions from the respective nominee. Please contact your trustee for further information.

Directly registered warrants (VP account)

No issue report or payment instruction will be sent out. Subscription must be made by simultaneous cash payment according to the instructions on the application form. The warrants are then replaced with interim shares (IA) pending registration at Bolagsverket.

The application form with instructions for payment will be available on the Company's website, www.addvisigroup.se, and on Mangold Fondkommission AB's website, www.mangold.se.

Adviser

Mangold Fondkommission is the financial adviser and Advokatfirman Schjødt is the legal advisor to ADDvise regarding the warrants.

For questions regarding the warrants, please contact:

Mangold Fondkommission AB
Tel: +46 8 5030 1595
E-mail: emissioner@mangold.se

For further information:

Hanna Myhrman, General Counsel
Tel: +46 709 82 92 23
E-mail: hanna.myhrman@addvisigroup.se

About ADDvise

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of approximately 10 subsidiaries organized into two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business - both geographically and product wise. ADDvise Group's shares are listed on Nasdaq First North Growth Market and Mangold Fondkommission AB, +46 8 503 015 50, ca@mangold.se, is the Company's Certified Adviser. Additional information is available at www.addvisigroup.com.